Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Advexin, chemotherapy combination shows promise in treating breast cancer
January 13th, 2005
Introgen Therapeutics, Inc., (INGN) reported data from its phase II trial evaluating Advexin combined with neoadjuvant chemotherapy in women with locally advanced breast cancer. Neoadjuvant treatments are administered prior to surgery and represent a novel and increasingly applied approach to make surgical tumor resections either more complete improving outcomes or less invasive facilitating breast conservation. Objective clinical responses with a greater than 50% reduction in tumor size were seen following the combined therapy in all of the patients. Complete tumor removal by subsequent surgery was achieved in 100% of the patients. The results of...
Source: Women's Health Weekly (2005-01-13)
|
